#Japan #Tokyo #StemCellResearch #EyeDiseaseTreatment #MesenchymalStemCells

New Insights into Eye Disease Treatment

In a groundbreaking development, StemCell Research Institute, in collaboration with the International University of Health and Welfare and the Eiwakai Medical Corporation, has signed a joint research contract aimed at developing a novel treatment for eye diseases utilizing mesenchymal stem cell-derived culture medium. This partnership heralds a new era in therapeutic applications for common yet challenging ocular conditions such as dry eye syndrome, corneal ulcers, and epithelial defects, conditions that affect many individuals in their daily lives.

Understanding Corneal Epithelial Defects

Corneal epithelial defects manifest as complications resulting from various factors, including trauma, infections, allergies, and post-surgical conditions. In addition, traditionally used ophthalmic treatments, such as eye drops and systemic medications like anticancer agents, can also induce these issues. Patients suffering from corneal epithelial defects often experience significant discomfort, visual disturbances, and increased infection risks, complicating their overall quality of life.

Conventional interventions have included artificial tears, dry eye medications, corticosteroid eye drops, and therapeutic soft contact lenses. While these treatments can be effective, severe cases may lead to prolonged epithelial defects, risking irreversible decline in ocular function. This has spurred demand for innovative treatment modalities that promote corneal epithelial regeneration, as existing therapies may not suffice.

The Role of Stem Cell-Derived Culture Medium

Recent advancements in cell therapy and tissue repair techniques have highlighted the potential of using cell-derived components, particularly culture medium from mesenchymal stem cells, in combating inflammation and promoting tissue repair. The collaborative research will assess the applicability of umbilical-derived mesenchymal stem cell culture medium in treating eye diseases, with an emphasis on the often-seen corneal epithelial defects in ophthalmology.

The research aims to validate the effectiveness of this approach and gather foundational knowledge that will eventually pave the way for clinical applications. The hope is to shift the paradigm in treating these ocular conditions, thus enhancing patient outcomes.

About the Participating Organizations

StemCell Research Institute

Founded in 1999, StemCell Research Institute operates under the corporate slogan, "New Medical Options for New Lives." The company has established a robust network with obstetrics and gynecology facilities to promote a cell bank business focused on regenerative medicine and cell therapy derived from perinatal tissues such as umbilical cords. With its foundational business, it also focuses on global and sustainable growth through investments and technological advancements in related fields, including femtech.

Headquarters: 1-21-19 Toranomon, Minato-ku, Tokyo, 105-0001
Website: stemcell.co.jp
Stock Number: 7096

International University of Health and Welfare

Established in 1995, the International University of Health and Welfare stands as Japan's first comprehensive university in medical welfare. It boasts five campuses with eleven faculties and 28 departments and operates six affiliated hospitals and approximately 65 related medical and welfare facilities across the nation. The institution emphasizes team-oriented medical practices and fosters developing global professionals while also prioritizing clinical and research progress toward new treatment methods.

Location: 2600-1 Kitakanemaru, Otawara, Tochigi, 324-8501
Website: iuhw.ac.jp

Eiwakai Medical Corporation

Founded in 2014, Eiwakai Medical Corporation is dedicated to providing compassionate care to safeguard the precious eyesight of its patients. The organization aims to deliver advanced team-based medical care, emphasizing close cooperation with other medical facilities to enhance the standard of medical care in the community. Recently, they have focused on supporting the development of medical devices and treatments while expanding global ophthalmic medical practices.

Location: 3-23-34 Kamikodanaka, Nakahara-ku, Kawasaki, Kanagawa
Website: eiwakai-groups.jp

Through this collaborative effort among leading institutions, the future of eye disease treatment looks optimistic, potentially offering new hope to patients suffering from debilitating eye conditions.